Survodutide

A dual glucagon and GLP-1 receptor agonist in late-stage trials for obesity and liver disease.

What research shows

Survodutide has randomized phase 2 evidence in both obesity and metabolic dysfunction associated steatohepatitis, with dose-dependent effects on weight and HbA1c. It is investigational: no marketing authorisation was found in the regulators we checked, so any material sold now is unapproved.

Evidence strength

Highest evidence grade among the graded claims: B. Grades reflect study strength, not benefit.

Safety context

See the safety section. Absence of a flag is not evidence of safety.

No endorsement

A grade reflects evidence strength, not a recommendation to use this compound; a strong grade can attach to a harmful effect.